Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of small-cap biopharma Intra-Cellular Therapies Inc (NASDAQ:ITCI) were nearly doubling Monday after a binary event panned out in favor of the company.
The shares are trading at their highest level since late 2016.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
FDA Approves Lumateperone
Intra-Cellular said the FDA has approved its lumateperone for treating schizophrenia.
Lumateperone, which goes by the trade name Caplyta, is an oral, once-daily medicine. Its efficacy is mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine receptors.
Intra-Cellular Developing Drug For Other Indications
Schizophrenia, a chronic disease often accompanied by depression and gradual deterioration of social functioning and cognitive ability, affects about 2.4 million adults in the U.S.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Most patients often discontinue treatment due to side effects such as weight gain and movement disorders.
"We believe Caplyta provides health care providers a new, safe and effective treatment option to help the millions of adult patients with schizophrenia," CEO Dr. Sharon Mates said in a statement.
Intra-Cellular is also developing Caplyta for bipolar depression; behavioral disturbances in patients with dementia, including Alzheimer's disease; depression and other neuropsychiatric and neurological disorders.
The company said it expects to commercially launch Caplyta late in the first quarter of 2020.
Intra-Cellular shares were jumping 181.03% to $34.96 at the time of publication.
Related Links:
The Week Ahead In Biotech: Correvio, Intra-Cellular Therapies Await FDA Decisions
Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.